All In MedTech

FDA Clearance Tracker · P170019-S034

FoundationOne CDx (FICDx)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 13, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 13, 2022

Approved

Time to decision

26 days

Received Mar 18, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170019-S034
Device name
FoundationOne CDx (FICDx)
Applicant location
Boston, MA
Received
Mar 18, 2022
Decided
Apr 13, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170019

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval of the clinical protocol entitled Statistical Analysis Plan for MK-3475 MSI-H FMI F1CDx Post Approval Analysis.

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.